key: cord-0790041-0zvf3sr2 authors: Zaqout, A.; Almaslamani, M. A.; Chemaitelly, H.; Hashim, S. A.; Ittaman, A.; Alimam, A.; Rustom, F.; Daghfal, J.; Abukhattab, M.; AlMukdad, S.; Kaleeckal, A. H.; Latif, A. N.; Butt, A. A.; Bertollini, R.; Al-Khal, A.; Omrani, A. S.; Abu-Raddad, L. J. title: Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild to moderate SARS-CoV-2 in Qatar date: 2022-04-22 journal: nan DOI: 10.1101/2022.04.21.22274060 sha: b286f8b0a2a38893d03924674ec8f1f8971d1e8d doc_id: 790041 cord_uid: 0zvf3sr2 Effectiveness of sotrovimab against severe, critical, or fatal COVID-19 was investigated in Qatar using a case-control study design at a time when BA.2 Omicron subvariant dominated incidence. Adjusted odds ratio of progression to severe, critical, or fatal COVID-19, comparing those sotrovimab-treated to those untreated, was 2.67-fold higher (95% CI: 0.60-11.91). individuals meeting study eligibility criteria. Notably, Qatar has young, diverse demographics, of that only 9% of its residents are ≥50 years of age, and 89% are expatriates from over 150 countries [4] . Cases (treatment group) included patients who received 500-mg, over 30 minutes infusion of sotrovimab, within 7 days of their PCR-positive or RAT-positive test. Controls were patients who were offered the treatment, but opted not to receive it. Patients were excluded from the treatment group if they showed symptoms of severe COVID-19 (oxygen saturation level <90% or required oxygen supplements) before receiving sotrovimab. Patients were excluded from the control group if they showed signs or symptoms of severe COVID-19 within 7 days of diagnosis. Cases and controls were exact-matched in a 1:2 ratio by COVID-19 vaccination status, prior infection status, sex, age group, nationality, comorbidity count, and epidemic phase (Deltadominated incidence versus Omicron-dominated incidence). Vaccination status and prior infection status of cases and controls were ascertained at the time of the PCR or RAT positive test. Prior infection was defined as a positive PCR or RAT test ≥90 days before the PCR or RAT positive test under study [5, 6] . The primary outcome of this study was progression to severe, critical, or fatal COVID-19 among those treated with sotrovimab compared with untreated patients. The large Omicron-wave exponential-growth phase in Qatar started on December 19, 2021 and peaked in mid-January, 2022 [7, 8] . Accordingly, infections diagnosed prior to December 19, Classification of case severity (acute-care hospitalizations) [9] , criticality (intensive-care-unit hospitalizations) [9] , and fatality [10] followed World Health Organization guidelines, and assessments were made by trained medical personnel independent of study investigators and using individual chart reviews, as part of a national protocol applied to every hospitalized COVID-19 patient. Details of COVID-19 severity, criticality, and fatality classification are found in Supplementary Text S1. Every hospitalized COVID-19 patient underwent an infection severity assessment every three days until discharge or death. Individuals who progressed to severe, critical, or fatal COVID-19 were classified based on their worst disease outcome, starting with death [10] , followed by critical disease [9] , and then severe disease [9] . The study database was linked to the national COVID-19 severity, criticality, and fatality database to ascertain disease outcome for every individual included in this study. Characteristics of treatment and control groups were described using frequency distributions and measures of central tendency. Group comparisons were performed using standardized mean differences (SMDs), with an SMD of <0.1 indicating adequate matching [11] . Adjusted odds ratios (AORs), comparing odds of progression to severe, critical, or fatal COVID-19 in the treatment versus control group, and associated 95% confidence intervals (CIs) were derived using conditional logistic regression, factoring the matching in the study design. Analysis was repeated only for a subgroup of patients at higher risk of severe forms of COVID-19. The latter included only immunocompromised individuals (solid organ or hematopoietic stem cell transplant recipients, patients receiving chemotherapy or immunosuppressive treatments, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. An additional analysis was conducted in which associations with severe, critical, or fatal COVID-19 were investigated using multivariable logistic regression to include all individuals eligible for sotrovimab treatment. AORs and associated 95% CIs were derived. P-values <0.05 were considered statistically significant. Statistical analyses were performed using Stata software, version 17.0, (Stata-Corp., College Station, Texas). Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards approved this retrospective study with a waiver of informed consent. The study was reported following the STROBE guidelines (Supplementary Table 1) . Of 3,364 individuals with documented SARS-CoV-2 infection who met sotrovimab treatment eligibility during the study period, 519 individuals consented and received the treatment. These constituted the treatment group. The remaining 2,845 individuals, who did not receive the treatment, constituted the controls. A total of 345 individuals in the treatment group were exactmatched in a 1:2 ratio to 583 individuals in the untreated control group. Supplementary Table 2 shows the baseline characteristics of study participants before and after matching. The median age was 40 years (interquartile range [IQR], 32-50) in the matched treatment group and 39 years (IQR, 33-46) in the matched control group. Less than 9% of cases were ≥60 years of age. Patients were of diverse nationality backgrounds and were predominantly vaccinated females. Most study participants were infected during the Omicron wave. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 3 shows baseline characteristics of the subgroup at higher risk of severe forms of COVID-19, before and after matching. Matched study groups were overall well balanced in the different analyses (Supplementary Tables 2 and 3 ). The AOR of progression to severe, critical, or fatal COVID-19, comparing those treated to those untreated, was 2.67 (95% CI: 0.60-11.91) ( Table 1 ). In the analysis including only the subgroup of patients at higher risk of severe forms of COVID-19, the AOR was 0.65 (95% CI: 0.17-2.48; Table 1 ). In the additional analysis using multivariable logistic regression on the full sample, the AOR of progression to severe, critical, or fatal COVID-19, comparing those treated to those untreated, was 1.80 (95% CI: 0.61-5.29) (Supplementary Table 4 ). In the subgroup analysis restricted to only patients at higher risk of severe forms of COVID-19, the AOR was 1.33 (95% CI: 0.44- Table 5 ). There was no evidence for reduced risk of severe forms of COVID-19 among individuals who received sotrovimab treatment per the FDA guidelines. This was also true for the subgroup of patients at higher risk of severe forms of COVID-19. These findings contrast with the effectiveness observed in a randomized control trial and other studies [2, [12] [13] [14] [15] , but agree with another study that found no evidence of a protective effect [16] . These findings may be explained by the fact that most infections during the study occurred during the Omicron wave and were predominantly due to BA.2 [7, 8] . Recent evidence demonstrated lower neutralizing activity of sotrovimab against the Omicron variant, and particularly against BA. 2 [17, 18] . The FDA has recently blocked use of sotrovimab in regions where BA.2 is dominant [3] . An alternative explanation is that those who consented and received the treatment may have perceived a need All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This study has limitations. While the sample size was not small, it may not be sufficient to precisely measure a small effect, given that we had to adjust the analysis for other factors that affect severity of COVID-19, including age, vaccination, prior infection, comorbidities, and infection variant status. It is possible that many patients declined sotrovimab treatment due to a perception of lower severity of Omicron infections. With the small proportion of Qatar's population ≥60 years of age [4] , our findings may not be generalized to countries in which elderly citizens represent a larger proportion of the population. As an observational study, investigated cohorts were neither blinded nor randomized, so unmeasured or uncontrolled confounding cannot be excluded. In conclusion, there was no evidence for a protective effect of sotrovimab in reducing COVID-19 severity in a setting dominated by the BA.2 subvariant. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Research Center for institutional support for the reagents needed for the viral genome sequencing. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article. Statements made herein are solely the responsibility of the authors. AZ, MAA, and ASO co-designed the study, led the database development, and co-wrote the manuscript. HC co-designed the study, performed the statistical analyses, and co-wrote the first draft of the article. LJA co-designed the study, led the statistical analyses, and co-wrote the first draft of the article. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, and to the writing of the manuscript. All authors have read and approved the final manuscript. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. None. The dataset of this study is a property of the Qatar Ministry of Public Health that was provided to the researchers through a restricted-access agreement that prevents sharing the dataset with a third party or publicly. Aggregate data are available within the manuscript and its Supplementary information. A limited dataset including the cases and controls and their associated variables that were used in the analysis can be made available for researchers upon request to the corresponding author of this study. Ong All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; COVID-19, coronavirus disease 2019. * Severity [9] , criticality [9] , and fatality [10] were defined according to the World Health Organization guidelines. † Cases and controls were exact-matched one-to-two by vaccination status, prior infection status, sex, age group, nationality group, comorbidity count, and epidemic phase. Matching factors are described in detail in Supplementary All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. of cases and controls............................................. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Organization (WHO) classification as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected person with "oxygen saturation of <90% on room air, and/or respiratory rate of >30 breaths/minute in adults and children >5 years old (or ≥60 breaths/minute in children <2 months old or ≥50 breaths/minute in children 2-11 months old or ≥40 breaths/minute in children 1-5 years old), and/or signs of severe respiratory distress (accessory muscle use and inability to complete full sentences, and, in children, very severe chest wall indrawing, grunting, central cyanosis, or presence of any other general danger signs)" [1] . Detailed WHO criteria for classifying SARS-CoV-2 infection severity can be found in the WHO technical report [1] . Critical COVID-19 disease was defined per WHO classification as a SARS-CoV-2 infected person with "acute respiratory distress syndrome, sepsis, septic shock, or other conditions that would normally require the provision of life sustaining therapies such as mechanical ventilation (invasive or non-invasive) or vasopressor therapy" [1] . Detailed WHO criteria for classifying SARS-CoV-2 infection criticality can be found in the WHO technical report [1] . COVID-19 death was defined per WHO classification as "a death resulting from a clinically compatible illness, in a probable or confirmed COVID-19 case, unless there is a clear alternative cause of death that cannot be related to COVID-19 disease (e.g. trauma). There should be no period of complete recovery from COVID-19 between illness and death. A death due to COVID-19 may not be attributed to another disease (e.g. cancer) and should be counted independently of preexisting conditions that are suspected of triggering a severe course of COVID-19". Detailed WHO criteria for classifying COVID-19 death can be found in the WHO technical report [2] . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Other analyses 17 Report other analyses done-eg analyses of subgroups and interactions, and sensitivity analyses All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Abbreviations: CMW, craft and manual worker; IQR, interquartile range; SMD, standardized mean difference. * Cases (individuals who received the sotrovimab treatment) were exact-matched with up to two controls (individuals who did not receive the sotrovimab treatment) by vaccination status, prior infection status, sex, age group, nationality group, comorbidity count, and epidemic phase. The final sample size thus includes cases that could be matched either to two controls or only to one control. This resulted in small differences between the groups. † SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD<0.1 indicates optimal balance in matching. ‡ SMD is for the mean difference between groups divided by the pooled standard deviation. § Vaccination status and prior infection status were ascertained at time of infection. ¶ These include Bangladeshis, Indians, Nepalese, Pakistanis, Sri Lankans, and Sudanese due to large proportions of these nationals being craft and manual workers. ** Before December 19, 2021 incidence in Qatar was dominated by the Delta variant whereas starting from December 19, 2021 incidence was dominated by the Omicron variant. Abbreviations: CMW, craft and manual worker; IQR, interquartile range; SMD, standardized mean difference. * These include immunocompromised individuals (solid organ or hematopoietic stem cell transplant recipients, patients receiving chemotherapy or immunosuppressive treatments, patients with severe immunodeficiency, and HIV patients), unvaccinated individuals, those ≥75 years of age, and pregnant women. † Cases (individuals who received the sotrovimab treatment) were exact-matched with up to two controls (individuals who did not receive the sotrovimab treatment) by vaccination status, prior infection status, sex, age group, nationality group, and epidemic phase. The final sample size thus includes cases that could be matched either to two controls or only to one control. This resulted in small differences between the groups. ‡ SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD<0.1 indicates optimal balance in matching. § SMD is for the mean difference between groups divided by the pooled standard deviation. ¶ Vaccination status and prior infection status were ascertained at time of infection. ** These include Bangladeshis, Indians, Nepalese, Pakistanis, Sri Lankans, and Sudanese due to large proportions of these nationals being craft and manual workers. † † Before December 19, 2021 incidence in Qatar was dominated by the Delta variant whereas starting from December 19, 2021 incidence was dominated by the Omicron variant. Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; CMW, craft and manual worker; COVID-19, coronavirus disease 2019; OR, odds ratio. * These include immunocompromised individuals (solid organ or hematopoietic stem cell transplant recipients, patients receiving chemotherapy or immunosuppressive treatments, patients with severe immunodeficiency, and HIV patients), unvaccinated individuals, those ≥75 years of age, and pregnant women. † Severity [1] , criticality [1] , and fatality [2] were defined according to the World Health Organization guidelines. ‡ Proportion of those who progressed to severe, critical, or fatal COVID-19 among those in predictor category. § Vaccination status and prior infection status were ascertained at time of infection. ¶ These include Bangladeshis, Indians, Nepalese, Pakistanis, Sri Lankans, and Sudanese due to large proportions of these nationals being craft and manual workers. ** Before December 19, 2021 incidence in Qatar was dominated by the Delta variant whereas starting from December 19, 2021 incidence was dominated by the Omicron variant. Monoclonal antibody therapies in the management of SARS-CoV-2 infection Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab Emergency use authorization (EUA) of sotrovimab Characterizing the Qatar advancedphase SARS-CoV-2 epidemic SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy A systematic review of the protective effect of prior SARS-CoV-2 infection on repeat infection Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar World Health Organization. COVID-19 clinical management: living guidance International guidelines for certification and classification (coding) of COVID-19 as cause of death Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trial World Health Organization. COVID-19 clinical management: living guidance International guidelines for certification and classification (coding) of COVID-19 as cause of death